NEWSROOM
Press releases
January 7th, 2025
Exciting News: Exothera Teams Up with Vaxthera on COVID-19 Vaccine Project
Read the press release
December 18th, 2024
Sun Biotech Selects Exothera for the Development of an Innovative Zika Virus Process
Read the press release
October 8th, 2024
Exothera announced the appointment of Cedric Volanti as CEO
June 11th, 2024
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
Read the press release
March 26, 2024
Exothera pledges to fast-track RNA therapies with expansion of world-first continuous-batch RNA manufacturing solution into North America
Read the press release
November 28, 2023
Exothera’s CTO Patrick Thiaville nominated as a member of Alliance for mRNA Medicines Board
Read the press release
August 16, 2023
NIH and Exothera collaborate to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US
Read the press release
June 28, 2023
Meissa Vaccines Enters into cGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate for Phase 2 Clinical Trials
Read the press release
March 22, 2023
Remedium and Exothera partner on scale-up and demonstration runs for AAV2-FGF18
Read the press release
February 1, 2023
Exothera announces the appointment of Darren Leva as Chief Business Officer
Read the press release
January 11, 2023
Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
Read the press release
July 6, 2022
Vaccizone selects Exothera for process development and GMP manufacturing of its SARS‑CoV‑2 vaccine based on proprietary ASC technology
Read the press release
June 16, 2022
PAT4CGT Consortium Announces Prestigious €4.7M Pathfinder Grant Awarded by European Innovation Council for the Development of Modular Cell & Gene Therapy Manufacturing Platform
Read the press release
June 15, 2022
Exothera announces industrial scale AAV manufacturing collaboration with LogicBio Therapeutics and Polyplus
Read the press release
June 9, 2022
Exothera develops exoREADY, a ready-to-use viral vector production platform, to accelerate advanced therapy manufacture at scale
Read the press release
April 12, 2022
ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle-Income Countries
Read the press release
March 31, 2022
Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0.
Read the press release
March 23, 2022
GMP certification for Exothera further expands its viral vector manufacturing capacity
Read the press release
March 1, 2022
IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines
October 27, 2021
Exothera announces the appointment of Hanna Lesch as Chief Technology Officer
September 9, 2021
GeneQuine selects Exothera to support the next stage of its osteoarthritis gene therapy development
July 1, 2021
Pall Corporation Secures Multi-Million Dollar Contract With Exothera
June 1, 2021
Univercells and Exothera announce Thibault Jonckheere as the new CEO of Exothera
May 20, 2021
Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine Target with Global Public Health Demand
March 24, 2021
CyanVac selects Exothera for the development and GMP manufacturing of its COVID-19 intranasal vaccine candidate for phase III clinical trial in Europe and the US
January 28, 2021
Exothera completes its range of state-of-the-art technologies by acquiring the new generation of the NevoLine™ Upstream platform for its new site in Belgium
